Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
March 22, 2019 Off

Alcohol Addiction – Pipeline Review, H1 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Alcohol Addiction – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. This latest Pharmaceutical…

March 22, 2019 Off

$69+ Billion Diabetes Therapies Market by 2023: Opportunities & Strategies – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Diabetes Therapies Global Market Opportunities And Strategies To 2023” report has been added to ResearchAndMarkets.com’s offering. This report…

Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent
March 22, 2019 Off

Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent

By BusinessWire

BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s…

Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline
March 22, 2019 Off

Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline

By Dino Mustafić

Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.

Neurotrope jumps in the Alzheimer’s solution chase, amid Biogen’s, Eisai’s dropping aducanunab trial
March 22, 2019 Off

Neurotrope jumps in the Alzheimer’s solution chase, amid Biogen’s, Eisai’s dropping aducanunab trial

By Dino Mustafić

Neurotrope said Friday, commenting Biogen Inc.’s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer’s disease, Phase 2 clinical trial using its drug Bryostatin during the second half of 2019.

ProMIS offeri potential significant advantage over aducanumab, learns from mistakes
March 22, 2019 Off

ProMIS offeri potential significant advantage over aducanumab, learns from mistakes

By Dino Mustafić

ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.

March 22, 2019 Off

Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

By BusinessWire

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer ST.…

Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
March 22, 2019 Off

Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

By BusinessWire

Application supported by the Phase 3 MAIA study for daratumumab in combination with lenalidomide and dexamethasone for the treatment of…

AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
March 22, 2019 Off

AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants

By BusinessWire

ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced…

March 22, 2019 Off

Whole Slide Imaging Market – Global Growth, Trends, and Forecasts 2019-2024 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Whole Slide Imaging Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…

Posts pagination

Previous 1 … 3,338 3,339 3,340 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine